Cholinesterase inhibitors as Alzheimer's therapeutics

K Sharma - Molecular medicine reports, 2019 - spandidos-publications.com
Alzheimer's disease (AD) is one of the most common forms of dementia. AD is a chronic
syndrome of the central nervous system that causes a decline in cognitive function and …

A review: Pharmacological aspects of metal based 1, 2, 4-triazole derived Schiff bases

W Zafar, SH Sumrra, ZH Chohan - European journal of medicinal chemistry, 2021 - Elsevier
Clinical reports have highlighted the radical increase of antibiotic resistance. As a result,
multidrug resistance has emerged as a serious threat to human health. Many organic …

A review on the biomedical efficacy of transition metal triazole compounds

SH Sumrra, W Zafar, M Imran… - Journal of Coordination …, 2022 - Taylor & Francis
From the apocalyptic era of antibiotic resistance, the scientific community around the world is
engaged in designing and develo** metal-based compounds to inhibit and control …

Triazole derivatives as inhibitors of Alzheimer's disease: current developments and structure-activity relationships

M Xu, Y Peng, L Zhu, S Wang, J Ji… - European journal of …, 2019 - Elsevier
Alzheimer's disease (AD) is a well known neurodegenerative disorder alarming millions of
people worldwide and the subsequent epidemiological statistics highlights the implication of …

Multitarget therapeutic strategies for Alzheimer's disease: Review on emerging target combinations

S Maramai, M Benchekroun, MT Gabr… - BioMed Research …, 2020 - Wiley Online Library
Neurodegenerative diseases represent nowadays one of the major health problems.
Despite the efforts made to unveil the mechanism leading to neurodegeneration, it is still not …

Pivotal role of nitrogen heterocycles in Alzheimer's disease drug discovery

S Kumari, K Maddeboina, RD Bachu, SHS Boddu… - Drug Discovery …, 2022 - Elsevier
Alzheimer's disease (AD) is a detrimental neurodegenerative disease that progressively
worsens with time. Clinical options are limited and only provide symptomatic relief to AD …

Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands

A Iraji, M Khoshneviszadeh, O Firuzi… - Bioorganic …, 2020 - Elsevier
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that effects 50 million
people worldwide. In this review, AD pathology and the development of novel therapeutic …

Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): a review

P Gehlot, S Kumar, VK Vyas, BS Choudhary… - Bioorganic & Medicinal …, 2022 - Elsevier
Alzheimer's disease (AD) is an irreversible, progressive neurological disorder characterized
by amyloid plaques, hyperphosphorylated tau protein (hyper p-tau), neuronal damage …

Pathogenesis of Alzheimer's Disease and Diversity of 1, 2, 3-Triazole Scaffold in Drug Development: Design Strategies, Structural Insights, and Therapeutic Potential

A Singh, K Singh, J Kaur, R Kaur… - ACS chemical …, 2023 - ACS Publications
Alzheimer's disease is a most prevalent form of dementia all around the globe and currently
poses a significant challenge to the healthcare system. Currently available drugs only slow …

Evaluating the effects of disubstituted 3-hydroxy-1H-pyrrol-2 (5H)-one analog as novel tyrosinase inhibitors

N Alizadeh, MH Sayahi, A Iraji, R Yazzaf… - Bioorganic …, 2022 - Elsevier
In the present study, a series of 3-hydroxy-1H-pyrrol-2 (5H)-one derivative were rationally
designed and synthesized. The structure of targeted compounds was confirmed by IR, 1 H …